#AP301
Alebund Pharmaceuticals Reports Promising Interim Results for the First Half of 2026#China#Shanghai#Alebund#AP301#Mircera
Alebund Pharmaceuticals Reports Promising Interim Results for the First Half of 2026
Alebund Pharmaceuticals has shared significant interim results for the first half of 2026, highlighting major advancements in clinical trials and commercialization strategies.
third-news.com
August 26, 2026 at 10:56 AM
Alebund Pharmaceuticals Completes Patient Enrollment for AP301 Trial Against Hyperphosphatemia#China#Shanghai#AP301#Hyperphosphatemia#Alebund_Pharmaceutical
Alebund Pharmaceuticals Completes Patient Enrollment for AP301 Trial Against Hyperphosphatemia
Alebund Pharmaceuticals has successfully finished patient enrollment in an important Phase III trial for AP301, aimed at treating hyperphosphatemia in CKD patients.
third-news.com
May 6, 2026 at 4:05 AM
Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston#China#Houston#Alebund#AP301#Hyperphosphatemia
Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston
Alebund Pharmaceuticals presented significant Phase 3 trial results for AP301 at the ASN 2025 Congress, showcasing its ability to reduce serum phosphate levels effectively.
third-news.com
November 7, 2025 at 12:08 PM